{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:00Z","timestamp":1789421400188,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Project in Lianyungang City","award":["SF2313"],"award-info":[{"award-number":["SF2313"]}]},{"name":"Science and Technology Development Fund of Xuzhou Medical University Affiliated Hospital","award":["XYFM202328"],"award-info":[{"award-number":["XYFM202328"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97125-w","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:41:06Z","timestamp":1744425666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytogenetic risk stratification combined with minimal residual disease status influences the therapeutic outcome and prognosis of multiple myelomas"],"prefix":"10.1038","volume":"15","author":[{"given":"Jianping","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianguo","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"97125_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood.2023020284","volume":"142","author":"M Mohty","year":"2023","unstructured":"Mohty, M., Avet-Loiseau, H., Malard, F. & Harousseau, J. L. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood 142, 1509\u20131517. https:\/\/doi.org\/10.1182\/blood.2023020284 (2023).","journal-title":"Blood"},{"key":"97125_CR2","doi-asserted-by":"publisher","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 10 https:\/\/doi.org\/10.1038\/s41572-024-00529-7 (2024).","DOI":"10.1038\/s41572-024-00529-7"},{"key":"97125_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. JAMA 327, 464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003 (2022).","journal-title":"JAMA"},{"key":"97125_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422 (2024).","journal-title":"Am. J. Hematol."},{"key":"97125_CR5","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"E Zamagni","year":"2022","unstructured":"Zamagni, E., Barbato, S. & Cavo, M. How I treat high-risk multiple myeloma. Blood 139, 2889\u20132903. https:\/\/doi.org\/10.1182\/blood.2020008733 (2022).","journal-title":"Blood"},{"key":"97125_CR6","doi-asserted-by":"publisher","first-page":"e70270","DOI":"10.1002\/cam4.70270","volume":"13","author":"D Liang","year":"2024","unstructured":"Liang, D. et al. Clinical outcome of induction treatment in the era of novel agents and the impact of the number of high-risk cytogenetic abnormalities (HRA) on prognosis of patients with newly diagnosed multiple myeloma (NDMM): insights from a multicenter study. Cancer Med. 13, e70270. https:\/\/doi.org\/10.1002\/cam4.70270 (2024).","journal-title":"Cancer Med."},{"key":"97125_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3760\/cma.j.cn121090-20230728-00036","volume":"45","author":"HX Zhou","year":"2024","unstructured":"Zhou, H. X. & Chen, W. M. Minimal residual disease assessment and progress in multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 45, 203\u2013208. https:\/\/doi.org\/10.3760\/cma.j.cn121090-20230728-00036 (2024).","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"97125_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo, M. et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 139, 835\u2013844. https:\/\/doi.org\/10.1182\/blood.2021011101 (2022).","journal-title":"Blood"},{"key":"97125_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat, R., Anderson, K. & Munshi, N. Role of minimal residual disease assessment in multiple myeloma. Haematologica 109, 2049\u20132059. https:\/\/doi.org\/10.3324\/haematol.2023.284662 (2024).","journal-title":"Haematologica"},{"key":"97125_CR10","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5 (2014).","journal-title":"Lancet Oncol."},{"key":"97125_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548\u2013567. https:\/\/doi.org\/10.1002\/ajh.25791 (2020).","journal-title":"Am. J. Hematol."},{"key":"97125_CR12","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6 (2016).","journal-title":"Lancet Oncol."},{"key":"97125_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12672-024-00891-8","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma. Discov Oncol. 15, 38. https:\/\/doi.org\/10.1007\/s12672-024-00891-8 (2024).","journal-title":"Discov. Oncol."},{"key":"97125_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao, Y. et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 24, 406. https:\/\/doi.org\/10.1186\/s12885-024-12077-0 (2024).","journal-title":"BMC Cancer"},{"key":"97125_CR15","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827 (2020).","journal-title":"Blood Adv."},{"key":"97125_CR16","doi-asserted-by":"publisher","unstructured":"Yee, A. J. & Raje, N. Minimal residual disease in multiple myeloma: why, when, where. Hematol. Am. Soc. Hematol. Educ. Program 37\u201345, (2021). https:\/\/doi.org\/10.1182\/hematology.2021000230 (2021).","DOI":"10.1182\/hematology.2021000230"},{"key":"97125_CR17","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva, B., San-Miguel, J. & Avet-Loiseau, H. MRD in multiple myeloma: does CR really matter? Blood 140, 2423\u20132428. https:\/\/doi.org\/10.1182\/blood.2022016170 (2022).","journal-title":"Blood"},{"key":"97125_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren, O. et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144, 359\u2013367. https:\/\/doi.org\/10.1182\/blood.2024024371 (2024).","journal-title":"Blood"},{"key":"97125_CR19","doi-asserted-by":"publisher","unstructured":"Ding, H. et al. Minimal residual disease in multiple myeloma: current status. Biomark. Res. 9 https:\/\/doi.org\/10.1186\/s40364-021-00328-2 (2021).","DOI":"10.1186\/s40364-021-00328-2"},{"key":"97125_CR20","doi-asserted-by":"publisher","first-page":"801851","DOI":"10.3389\/fonc.2021.801851","volume":"11","author":"C Charalampous","year":"2021","unstructured":"Charalampous, C. & Kourelis, T. Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications. Front. Oncol. 11, 801851. https:\/\/doi.org\/10.3389\/fonc.2021.801851 (2021).","journal-title":"Front. Oncol."},{"key":"97125_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 3, 28\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3160 (2017).","journal-title":"JAMA Oncol."},{"key":"97125_CR22","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1111\/bjh.17391","volume":"193","author":"R Popat","year":"2021","unstructured":"Popat, R. et al. Using depth of response to stratify patients to front line autologous stem cell transplant: results of the phase II PADIMAC myeloma trial. Br. J. Haematol. 193, e19\u2013e22. https:\/\/doi.org\/10.1111\/bjh.17391 (2021).","journal-title":"Br. J. Haematol."},{"key":"97125_CR23","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta, J. J. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J. Clin. Oncol. 35, 2900\u20132910. https:\/\/doi.org\/10.1200\/JCO.2016.69.2517 (2017).","journal-title":"J. Clin. Oncol."},{"key":"97125_CR24","doi-asserted-by":"publisher","first-page":"776920","DOI":"10.3389\/fonc.2022.776920","volume":"12","author":"Q Sun","year":"2022","unstructured":"Sun, Q. et al. Prognostic significance of the stage at which an MRD-Negative status is achieved for patients with multiple myeloma who received ASCT. Front. Oncol. 12, 776920. https:\/\/doi.org\/10.3389\/fonc.2022.776920 (2022).","journal-title":"Front. Oncol."},{"key":"97125_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288 (2020).","journal-title":"Blood"},{"key":"97125_CR26","doi-asserted-by":"publisher","unstructured":"Rocchi, S., Zannetti, B. A., Marconi, G. & Lanza, F. Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy. Cells 13 https:\/\/doi.org\/10.3390\/cells13100853 (2024).","DOI":"10.3390\/cells13100853"},{"key":"97125_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva, B. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J. Clin. Oncol. 38, 784\u2013792. https:\/\/doi.org\/10.1200\/JCO.19.01231 (2020).","journal-title":"J. Clin. Oncol."},{"key":"97125_CR28","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/jco.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute, R. M. et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of Lenalidomide maintenance and molecular risk. J. Clin. Oncol. 40, 2889\u20132900. https:\/\/doi.org\/10.1200\/jco.21.02228 (2022).","journal-title":"J. Clin. Oncol."},{"key":"97125_CR29","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456\u20132464. https:\/\/doi.org\/10.1182\/blood-2018-06-858613 (2018).","journal-title":"Blood"},{"key":"97125_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea, I. et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 137, 49\u201360. https:\/\/doi.org\/10.1182\/blood.2020006731 (2021).","journal-title":"Blood"},{"key":"97125_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41408-023-00943-2","volume":"13","author":"M Ozga","year":"2023","unstructured":"Ozga, M. et al. Concomitant 1q\u2009+\u2009and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma. Blood Cancer J. 13, 167. https:\/\/doi.org\/10.1038\/s41408-023-00943-2 (2023).","journal-title":"Blood Cancer J."},{"key":"97125_CR32","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa, L. J. et al. Carfilzomib, Lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 2901\u20132912. https:\/\/doi.org\/10.1200\/JCO.21.01935 (2022). Daratumumab.","journal-title":"J. Clin. Oncol."},{"key":"97125_CR33","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1097\/HS9.0000000000000942","volume":"7","author":"K Ramasamy","year":"2023","unstructured":"Ramasamy, K. et al. Measurable residual disease testing in multiple myeloma routine clinical practice: a modified Delphi study. Hemasphere 7, e942. https:\/\/doi.org\/10.1097\/HS9.0000000000000942 (2023).","journal-title":"Hemasphere"},{"key":"97125_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jtct.2023.08.031","volume":"29","author":"O Pasvolsky","year":"2023","unstructured":"Pasvolsky, O. et al. Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma. Transpl. Cell. Ther. 29, 757\u2013762. https:\/\/doi.org\/10.1016\/j.jtct.2023.08.031 (2023).","journal-title":"Transpl. Cell. Ther."},{"key":"97125_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"KK Nishimura","year":"2020","unstructured":"Nishimura, K. K. et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 4, 422\u2013431. https:\/\/doi.org\/10.1182\/bloodadvances.2019000524 (2020).","journal-title":"Blood Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97125-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:03:01Z","timestamp":1744815781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97125-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97125"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97125-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the First People\u2019s Hospital of Lianyungang (No. KY-20240110001-02), and informed consent was obtained prior to the experiment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"12545"}}